Cleveland Clinic researchers have shown for the first time how a class of advanced prostate cancer drugs are processed in the body and how their anti-tumor activity might change depending on how they are metabolized. Their pre-clinical findings, just published in Cell Chemical Biology, may lay the foundation for improving therapies for treatment-resistant, aggressive prostate cancer.
Anticancer agents targeting microtubule from marine sources hold great potential in the field of cancer therapeutics and are gradually advancing in the clinical setup.
Scientists have developed a three-in-one blood test that could transform treatment of advanced prostate cancer through use of precision drugs designed to target mutations in the BRCA genes. By testing cancer DNA in the bloodstream, researchers found they could pick out which men with advanced prostate cancer were likely to benefit from treatment with exciting new drugs called PARP inhibitors.
The winning image, presented by German researchers at the 2017 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), clearly demonstrates how combining the advantages of 68Ga-PSMA PET and intraoperative gamma and fluorescence imaging results in better tumor identification before and during surgery.
Simultaneous injections of the radiopharmaceuticals fluorine-18 fluorodeoxyglucose (18F-FDG) and 18F-sodium fluoride (18F-NaF) followed by quantitative scanning significantly improves image quality and detection of bone metastases at a lower dose, according to research presented at the 2017 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI).
A new study that includes data from four Australian medical centers shows that Ga-68 Prostate Specific Membrane Antigen (PSMA) PET/CT detects prostate cancer not caught by more conventional imaging, thus affecting treatment plans. The research was presented at the 2017 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI).
Patients who have aggressive prostate cancer could be identified by a highly accurate and simple blood test, according to an early study by Queen Mary University of London (QMUL).
In a study published today in Cancer Cell, Moffitt Cancer Center researchers report that a newly discovered epigenetic mechanism can lead to the development of castration-resistant prostate cancer.
Researchers presenting a preclinical study at the 2017 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) demonstrated the efficacy and optimal dose for targeted photodynamic therapy (tPDT) to treat prostate cancer before and during surgery. Prostate-specific membrane antigen (PSMA) was targeted with an anti-PSMA antibody radiolabeled with the tracer indium-111 (111In) and coupled with specialized photosensitizers that cause cell destruction upon exposure to near-infrared (NIR). The combined formula is 111In-DTPA-D2B-IRDye700DX.
A new diagnostic developed by Alberta scientists will allow men to bypass painful biopsies to test for aggressive prostate cancer. The test incorporates a unique nanotechnology platform to make the diagnostic using only a single drop of blood, and is significantly more accurate than current screening methods.